Get the Stockscreener App
39.55
2.08%
-0.84
After Hours:
39.54
-0.010
-0.03%
Gsk Plc Adr stock is traded at $39.55, with a volume of 4.39M.
It is down -2.08% in the last 24 hours and up +8.24% over the past month.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
See More
Previous Close:
$40.39
Open:
$39.55
24h Volume:
4.39M
Relative Volume:
0.96
Market Cap:
$80.51B
Revenue:
$40.10B
Net Income/Loss:
$3.26B
P/E Ratio:
24.98
EPS:
1.5831
Net Cash Flow:
$4.57B
1W Performance:
+1.72%
1M Performance:
+8.24%
6M Performance:
-4.97%
1Y Performance:
-6.55%
1-Day Range:
$39.27
$39.80
1-Week Range:
$38.92
$40.47
52-Week Range:
$31.71
$45.92
Gsk Plc Adr Stock (GSK) Company Profile
Name
Gsk Plc Adr
Sector
Industry
Phone
-
Address
-
Compare GSK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
39.55 | 80.51B | 40.10B | 3.26B | 4.57B | 1.5831 |
|
LLY
Lilly Eli Co
|
837.01 | 751.78B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
212.25 | 374.70B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
79.00 | 350.69B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
162.99 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
94.02 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Nov-12-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-24 | Downgrade | UBS | Buy → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| Mar-04-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-13-24 | Upgrade | Citigroup | Neutral → Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Jan-03-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Mar-17-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-27-23 | Resumed | Goldman | Buy |
| Jan-03-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-11-22 | Downgrade | UBS | Neutral → Sell |
| Sep-15-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Sep-08-22 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-21-22 | Resumed | Citigroup | Neutral |
| Feb-11-22 | Downgrade | DZ Bank | Buy → Hold |
| Nov-05-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Jun-24-21 | Upgrade | Deutsche Bank | Sell → Hold |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-04-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-20-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-15-21 | Initiated | Deutsche Bank | Hold |
| Nov-02-20 | Upgrade | Liberum | Hold → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Feb-12-20 | Downgrade | Shore Capital | Hold → Sell |
| Jan-16-20 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-19 | Initiated | SVB Leerink | Outperform |
| Nov-21-19 | Upgrade | UBS | Neutral → Buy |
| Oct-11-19 | Upgrade | Cantor Fitzgerald | Hold → Buy |
| Sep-03-19 | Resumed | Citigroup | Neutral |
| Sep-03-19 | Upgrade | Societe Generale | Sell → Buy |
| Aug-13-19 | Resumed | JP Morgan | Neutral |
| Jun-17-19 | Resumed | Morgan Stanley | Underweight |
| Mar-08-19 | Downgrade | Shore Capital | Buy → Hold |
| Feb-22-19 | Downgrade | UBS | Buy → Neutral |
| Jan-14-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Aug-30-18 | Downgrade | Liberum | Buy → Hold |
| Apr-04-18 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-22-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-09-18 | Upgrade | Kepler | Reduce → Hold |
View All
Gsk Plc Adr Stock (GSK) Latest News
How Do Things Look For GSK Plc ADR (NYSE: GSK) In The Short-Term? - Stocks Register
Pfizer Offloads Its Last 7% Stake In Consumer Health Haleon For Over $3 Billion - Benzinga
GSK Lead Plaintiff Deadline Approaching – Contact Robbins - GlobeNewswire
GSK Lead Plaintiff Deadline Approaching – Contact Robbins LLP for Information About How to Lead the GSK PLC Class Action - TradingView
Why GSK (GSK) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive - Zacks Investment Research
Deadline Alert: GSK plc. (GSK) Investors Who Lost Money - GlobeNewswire
Deadline Alert: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming DeadlinesGSK - PR Newswire
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe - Zacks Investment Research
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More - Yahoo Finance
The Best Women-Led Companies to Own: 2025 Edition - Morningstar
GSK’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Why weight-loss drugs are the top target of Medicare price negotiations - Equities News
GSK Securities Class Action: GSK PLC Investors Should Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the GSK Class Action Lawsuit - The Malaysian Reserve
5 Undervalued Stocks That Crushed Q4 Earnings - Morningstar
Shareholder Rights Law Firm Robbins LLP Reminds GSK Investors with Large Losses to Seek Advice on Leading the GSK PLC Class Action - PR Newswire
A closer look at Gold Fields Ltd ADR’s (GFI) current quarter earnings projections - US Post News
Law Offices of Frank R. Cruz Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action - Business Wire
Deadline Approaching: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith - Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action - Business Wire
Is GSK Plc ADR (GSK) worth investing in despite its undervalued state? - US Post News
Chewy Inc (CHWY) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Law Offices of Howard G. Smith Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action - Business Wire
GSK PLC Stockholder Notice: Shareholder Rights Law Firm - GlobeNewswire
O’Reilly Automotive, Inc [ORLY] stock for 2,179,380 USD was sold by CONN TAMARA F. - Knox Daily
Buying Buzz: GSK Plc ADR [GSK] 10% Owner GSK plc purchases 2,791,930 shares of the company - Knox Daily
Bear Of The Day: GSK PLC (GSK) - Yahoo Finance
MNKD Shares Experience Surge in Value - Knox Daily
Torrid Holdings Inc [CURV] Shares Jump Approximately 29.38% Over the Year - Knox Daily
D-Wave Quantum Inc [QBTS] Records 200-Day SMA of $2.33 - Knox Daily
Rumble Inc [RUM] Records 50-Day SMA of $10.53 - Knox Daily
Investor Alert: Robbins LLP Informs Stockholders of the GSK PLC Class Action - PR Newswire
Rosen Law Firm Urges GSK plc (NYSE: GSK) Investors with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Gsk Plc Adr Stock (GSK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):